ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Sponsor: Acerta Pharma BV
This PHASE1/PHASE2 trial investigates Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia and is currently ongoing. Acerta Pharma BV leads this study, which shows 28 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
28 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
▶ Show 23 earlier versions
-
Dec 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2024 — May 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Dec 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Dec 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2022 — May 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Unknown Status → Active Not Recruiting
-
Feb 2021 — May 2021 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Unknown Status → Active Not Recruiting
-
Feb 2019 — Mar 2019 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Acerta Pharma BV
For direct contact, visit the study record on ClinicalTrials.gov .